Nordic Issuing

Ongoing case

Amniotics AB

Back to all cases

Amniotics AB

28 May - 11 Jun 2021IPO

Amniotics AB was created from the discovery of a new stem cell source in amniotic fluid. Based on a decade of research at the internationally recognized Lund University’s stem cell center and hospital, the company is pioneering the harvesting and propagation of tissue-specific mesenchymal stem cells (MSCs).

Researchers and founders of the company, pediatrician Marcus Larsson, obstetrician Andreas Herbst and stem cell specialist Niels-Bjarne Woods discovered a new type of stem cells in amniotic fluid that have unique properties for applications in regenerative medicine. Their vision is to contribute to the successful treatment of diseases by providing the best stem cells for medical applications.

The company is currently advancing Pulmostem ™ for clinical development. The drug candidate targets severe inflammatory and fibrotic lung disease. The first patient is expected to start treatment during the first half of 2022. The start of the clinical study will be another important milestone for the company.

Read more on the company's website

The offer in summary

Subscription period: 28 May - 11 June 2021

Subscription price: 22,5 SEK per share

Minimum aquisition : 250 shares corresponding to 5 625 SEK

Volume of issuance: The offer comprises a maximum of 3,555,556 shares. Upon full subscription of the offer, the company will receive approximately 80 MSEK

ISIN: SE0014398848

The offer price has been determined in consultation with Redeye who has acted as financial advisor.


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.